KORU Medical Systems (NASDAQ:KRMD) Price Target Raised to $8.00 at B. Riley Financial

KORU Medical Systems (NASDAQ:KRMD) had its price target hoisted by investment analysts at B. Riley Financial from $7.00 to $8.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley Financial’s price target would indicate a potential upside of 83.02% from the company’s current price.

A number of other equities research analysts also recently weighed in on KRMD. Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Thursday, January 22nd. Craig Hallum reaffirmed a “buy” rating and set a $7.00 target price on shares of KORU Medical Systems in a report on Tuesday, January 13th. Wall Street Zen upgraded shares of KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 12th. Canaccord Genuity Group increased their price target on KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Lake Street Capital lifted their price objective on KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.50.

KORU Medical Systems Trading Up 1.4%

KORU Medical Systems stock traded up $0.06 during mid-day trading on Friday, hitting $4.37. The stock had a trading volume of 225,321 shares, compared to its average volume of 197,323. The stock has a 50-day simple moving average of $5.13 and a two-hundred day simple moving average of $4.79. The stock has a market capitalization of $202.46 million, a PE ratio of -54.50 and a beta of 0.47. KORU Medical Systems has a 12 month low of $1.86 and a 12 month high of $6.61. The company has a current ratio of 2.48, a quick ratio of 1.92 and a debt-to-equity ratio of 0.01.

KORU Medical Systems (NASDAQ:KRMD) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. KORU Medical Systems had a negative return on equity of 22.43% and a negative net margin of 9.49%.The firm had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $10.90 million. As a group, sell-side analysts forecast that KORU Medical Systems will post -0.13 EPS for the current year.

Hedge Funds Weigh In On KORU Medical Systems

Several institutional investors and hedge funds have recently modified their holdings of KRMD. Lakewood Asset Management LLC raised its holdings in KORU Medical Systems by 2.8% during the 4th quarter. Lakewood Asset Management LLC now owns 73,945 shares of the company’s stock worth $430,000 after buying an additional 2,000 shares during the period. BNP Paribas Financial Markets increased its position in shares of KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after acquiring an additional 3,478 shares in the last quarter. White Pine Capital LLC increased its position in shares of KORU Medical Systems by 1.6% during the second quarter. White Pine Capital LLC now owns 225,425 shares of the company’s stock worth $807,000 after acquiring an additional 3,526 shares in the last quarter. Barclays PLC raised its holdings in shares of KORU Medical Systems by 8.8% during the fourth quarter. Barclays PLC now owns 67,442 shares of the company’s stock worth $392,000 after acquiring an additional 5,457 shares during the period. Finally, Invesco Ltd. lifted its position in KORU Medical Systems by 24.8% in the 4th quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock valued at $162,000 after acquiring an additional 5,546 shares in the last quarter. 58.60% of the stock is currently owned by institutional investors and hedge funds.

More KORU Medical Systems News

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: KORU reported fourth‑quarter revenue growth and a small EPS beat (Q4 EPS -$0.01 vs. consensus -$0.02) and matched revenue expectations, showing improvement vs. a year ago. This supports the stock’s upside today. KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: The company announced ~20% revenue growth for Q4 and full‑year 2025, delivered positive adjusted EBITDA, and initiated FY‑2026 guidance (revenue range roughly $47.5M–$50.0M), giving investors a clearer near‑term outlook. KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — a regulatory clearance that can support European commercialization and recurring revenue potential. KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
• Neutral Sentiment: KORU held its Q4 earnings call; the transcript provides details on growth drivers, product adoption, and margin trends for investors who want management color. KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: The company announced a CEO transition: longtime CEO Linda Tharby will retire effective June 30, 2026 and Adam Kalberma has been appointed. Leadership change adds execution risk uncertainty but also a planned succession. KORU Medical Systems Announces CEO Transition
• Negative Sentiment: Despite progress, KORU remains GAAP unprofitable (negative net margin ~9.5% and negative ROE) and posted a small per‑share loss; continued losses and modest scale could limit valuation expansion until profitability sustainably improves. Earnings release and financial details

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.